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Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that preferentially affects joints, and characterized by an
approximately two-fold increased risk of cardiovascular diseases compared with the general population. Beyond
classical cardiovascular risk factors, systemic inflammatory markers are primarily involved. Hence, anti-inflammatory
strategies such as homocysteine-lowering interventions are warranted. Indeed, hyperhomocysteinemia is commonly
found in RA patients as a result of both genetic and non-genetic factors including older age, male gender, disease-specific
features and disease-modifying antirheumatic drugs. Most importantly in the pathophysiology of hyperhomocysteinemia
and its related cardiovascular diseases in RA, there is a bi-directional link between immuno-inflammatory activation and
hyperhomocysteinemia. As such, chronic immune activation causes B vitamins (including folic acid) depletion and
subsequent hyperhomocysteinemia. In turn, hyperhomocysteinemia may perpetrate immuno-inflammatory stimulation via
nuclear factor ƙappa B enhancement. This chronic immune activation is a key determinant of hyperhomocysteinemia-
related cardiovascular diseases in RA patients. Folate, a homocysteine-lowering therapy could prove valuable for
cardiovascular disease prevention in RA patients in the near future with respect to homocysteine reduction along with
blockade of subsequent oxidative stress, lipid peroxidation, and endothelial dysfunction. Thus, large scale and long term
homocysteine-lowering clinical trials would be helpful to clarify the association between hyperhomocysteinemia and
cardiovascular diseases in RA patients and to definitely state conditions surrounding folic acid supplementation. This article
reviews direct and indirect evidence for cardiovascular disease prevention with folic acid supplementation in RA patients.
Keywords: Rheumatoid arthritis, Cardiovascular diseases, Prevention, Inflammatory biomarkers, Hyperhomocysteinemia,
Folic acid supplementation
Background
Rheumatoid arthritis (RA) is a systemic inflammatory dis-
ease characterized by chronic symmetric and erosive syno-
vitis that preferentially affects peripheral joints. RA patients
have an approximately two-fold increased risk of myocar-
dial infarction, cerebrovascular events and deep venous
thrombosis as well as a 60 % increased risk for cardiovascu-
lar diseases (CVD) compared with the general population
[1–3]. Irrespective of traditional cardiovascular risk factors,
systemic inflammatory mediators characteristic of RA are
primarily involved [1].
Homocysteine is a sulfhydryl-containing amino acid
mainly formed from the essential amino acid methio-
nine. Its plasma concentration depends on age, sex,
lifestyle factors-(coffee consumption, smoking, physical
activity, alcohol)-, genetic mutations leading to a severely
diminished activity of the enzymes involved in homocyst-
eine catabolism, drugs and diseases interfering with its
metabolism, and most importantly with B vitamins intake.
Since B-group vitamins (folic acid, pyridoxine and cobala-
mine) are involved in homocysteine catabolism, their
plasma levels are inversely associated with that of
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homocysteine [4]. Thus, hyperhomocysteinemia (HHcy)
which refers to fasting plasma homocysteine concentra-
tions ≥ 15 μM [4], is associated with decreased folate
levels. HHcy is a well-known cardiovascular risk factor in
the general population [4, 5], and in RA patients [6, 7].
Considering the CVD epidemic in RA patients and the
important role of systemic inflammation, anti-inflammatory
strategies such as homocysteine-lowering interventions ap-
pear necessary. This paper reviews direct and indirect
evidence for CVD prevention with folic acid supplementa-
tion in RA patients.
Hyperhomocysteinemia in rheumatoid arthritis
HHcy is common among RA patients, as a consequence
of both genetic and non-genetic factors associated with
the disturbance of homocysteine metabolism [7–22].
Genetic risk factors are essentially represented by the
methylenetetrahydrofolate reductase (MTHFR) 677C > T
homozygous or heterozygous genotype which results in
impaired homocysteine methylation to form methionine
[8]. Whereas non-genetic factors include older age [9, 10],
male gender [9, 10], RA-specific features [4, 7, 11–22],
and disease-modifying antirheumatic drugs (DMARDs)
[23–28] (Fig. 1).
RA-specific features that influence the development of
HHcy are mainly immuno-inflammatory activation to-
gether with extra-articular features (e.g., gastrointestinal
disorders and kidney dysfunction), and their resultant B
vitamins (folic acid, pyridoxine and cobalamine) deficiency
[4, 7, 11–20]. Antiphospholipid (aPL) autoantibodies could
contribute to a lesser extent [21, 22]. In particular, CD4
+CD28− cells found in RA patients produce interferon
gamma (IFN-γ) [11–13]. The latter cytokine activates T
helper 1 (Th1) cells that spill over pro-inflammatory cyto-
kines (tumor necrosis factor alpha [TNF-α], interleukin-1
[IL-1], interleukin-6 [IL-6]) [11, 13]. These cytokines per-
petually stimulate excess monocyte/macrophage produc-
tion of reactive oxygen species (ROS) free radicals, thus
Fig. 1 Homocysteine metabolism and major factors associated with hyperhomocysteinemia in rheumatoid arthritis patients. MTHFR methylene
tetrahydrofolate; CBS cystathione β synthase; BHMT betaine homocysteine methyltransferase; MS methionine synthase; Vit vitamin; DMARDs
disease-modifying antirheumatic drugs. Vit B9 depletion owing to immuno-inflammatory activation, DMARDs, and gastrointestinal disturbance impairs
the MTHFR vit B9-dependent remethylation pathway together with the MTHFR C677T mutation; vit B12 depletion owing to both immuno-inflammatory
activation and gastrointestinal disturbance impairs the MS vit B12-dependent remethylation pathway; vit B6 depletion owing to immuno-inflammatory
activation and gastrointestinal disturbance impairs the CBS vit B6-dependent transsulfuration pathway
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causing cellular damage [11]. The net result is a long-term
shift in immuno-inflammatory activation, with antioxidant
enzymes overloaded by excess ROS [11–13]. Then, other
oxidation-sensitive molecules such as B vitamins (includ-
ing folate) are targeted by ROS [11], and rapid synthesis of
deoxyribonucleic acid (DNA) occurs within immunocom-
petent cells [14]. Hence, both oxidative stress and
increased mitosis account for B vitamins deficiency. This
deficiency could be exacerbated by gastrointestinal distur-
bances [15–20]. Indeed, B vitamins are absorbed across
the small and large intestinal mucosa through active trans-
port and passive diffusion [15–19]. Concerning folic acid
absorption, the dietary vitamin B9 is transported by the
mucosal proton-coupled folate-transporter across the
apical brush-border membrane of the bowel, whereas the
vitamin B9 from commensal bacteria is predominantly
absorbed in the colon [15, 16]. However, RA is associated
with frequent occult gut inflammation (due to the com-
bination of both intestinal immune activation and the use
of anti-inflammatory agents) which alters the mucosal
structure and permeability [15, 19]. Furthermore, decre-
mented intestinal microbiota has been reported in RA
patients [20]. Hence, gastrointestinal disorders may reduce
folic acid uptake in RA populations. In turn, folic acid de-
ficiency along with vitamins B6 and B12 deficiencies cause
homocysteine accumulation, given that they are co-factors
for homocysteine catabolism [4, 7]. Homocysteine may
further accumulate in RA patients with co-morbid kid-
ney dysfunction since kidneys are key organs for the
metabolism of homocysteine [4]. On the other hand,
Seriolo and collaborators observed significantly incremen-
ted serum homocysteine concentration in aPL-positive fe-
male RA patients compared to their aPL-negative RA
counterparts and to non-RA controls (16.6 ± 5.6 mol/l vs
13.9 ± 5.1 mol/l and 9.3 ± 4.1 mol/l, respectively; p <0.01
and p <0.0001) [21]. This finding together with the high
prevalence of aPL autoantibodies (28 %) in RA patients
[22] is suggestive of the role of aPL in the elevation of
plasma homocysteine in RA patients, but the mechanistic
link is still obscure.
DMARDs, essentially methotrexate, cause HHcy via
folate depletion [23–28]. This requires inhibition of
dihydrofolate reductase-an enzyme involved in homo-
cysteine remethylation pathway [8, 23, 24]. Noteworthy,
the effect of methotrexate is exacerbated when it is com-
bined with sulfasalazine [13], or in patients exhibiting
the MTHFR 677C > T genotype [8].
Association between hyperhomocysteinemia and
cardiovascular diseases
In the general population
HHcy is independently associated with coronary, cerebro-
vascular, and peripheral arterial diseases, as well as deep
veinous thrombosis in the general population [4, 5]. Three
main pathophysiological changes intimately connected
form the basis of HHcy-associated CVD [4, 29–33]: i) oxi-
dative stress [4, 29–33], ii) rise in asymmetric dymethylar-
ginine (ADMA) [31–33], iii) propensity for thrombosis [4,
7] (Fig. 2).
In situations of HHcy, homocysteine generates potent
ROS free radicals through auto-oxidization of its highly
active sulfhydryl group [29]. Continuous exposure of
endothelial cells to higher homocysteine concentrations
inhibits glutathione peroxidase, an enzyme that nor-
mally protects them against oxidative stress [4]. To-
gether, these results indicate that HHcy induces
vascular oxidative stress. Considering the physiological
synthesis of nitric oxide (NO) by endothelial cells, vas-
cular oxidative stress is responsible for reduced NO bio-
availability [4, 29]. Endothelium-dependent NO levels
may be further decreased by the reaction of NO with
homocysteine at higher plasma homocysteine concen-
trations to form S-nitroso-homocysteine [4]. Of special
relevance, reduced NO bioavailability subsequently in-
duces endothelial dysfunction given the beneficial ef-
fects of the latter molecule (vascular tone regulation,
inhibition of platelet activation, adhesion and aggrega-
tion, modulation of smooth cell proliferation and of
endothelial-leukocyte interaction) [4, 29, 30]. In parallel,
HHcy may dramatically increase the plasma concentra-
tion of ADMA-an endogenous nitric oxide synthase
(NOS) inhibitor-by stimulation of its synthesis and in-
hibition of dimethylarginine dymethylaminohydrolase,
the principal enzyme responsible for ADMA clearance
[31]. ADMA is formed after proteolysis of proteins con-
taining methylated arginine residues. Protein-arginine
methylation is facilitated by protein methyltransferase
enzymes which use S-adenosylmethionine (SAM) as the
methyl donor group; SAM being released by adenosine
triphosphate-activated L-methionine following homo-
cysteine methylation [31, 32]. Through endothelial NOS
inhibition, ADMA stimulates vascular oxidative stress,
and consequently reduces NO bioavailability [4, 33]. Be-
sides, ADMA depletes endothelial cells; thus worsening
impairment of NO levels [33]. Taken together, HHcy in-
duces endothelial dysfunction by reduction of NO levels
through oxidative stress, formation of S-nitroso-
homocysteine and raised ADMA production [4, 29–33].
Remarkably, atherogenesis is a complex process which
likely starts by endothelial dysfunction [29–35], an“im-
paired endothelium-dependent blood-vessel dilation in
response to a stimulus” [34]. Indeed, biological markers of
endothelial dysfunction (Intracellular adhesion molecule-
1, vascular cell adhesion molecule- 1, and P-selectin) are
raised within the endothelium in the initial phase of ath-
erosclerosis [34, 35]. Besides, these molecules may pro-
mote monocytes entry into the arterial wall where they
become macrophages subsequently capturing oxidized
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low density lipoprotein (ox-LDL) molecules [34]. The
resultant atherosclerotic plaque progression is under
control of elevated cytokines released by inflammatory
cells including ox-LDL fed macrophages termed “foam
cells” [34]. Concurrent vascular smooth-muscle cell pro-
liferation reinforces the plaque, and matrix metallopro-
teinases produced contributes to elastin and collagen
breakdown within the arterial wall. Subsequent vessel fis-
suring is accompanied by entry of coagulation factors and
platelet adherence that result in thrombosis, the late phase
of atherosclerosis [35]. Noteworthy, HHcy stimulates
endothelial dysfunction [4, 29–33], and lipid peroxidation
[29–33] through oxidative stress and raised ADMA
production. Furthermore, ADMA induces and amplifies
macrophage transformation to foam cells within the arter-
ial wall [4], and vascular smooth-muscle-cell proliferation
[4]. Moreover, HHcy predisposes to thrombosis through
platelet adhesion/activation and elevated production of
clotting molecules (von Willebrand factor, factor V, pro-
tein C, tissue factor, lipoprotein (a) bounded to fibrin) [4]
that can enter fissured arteries as well as impaired
thrombolysis. Taken collectively, it is likely that HHcy dir-
ectly and indirectly stimulates the atherosclerotic process
throughout its development from the beginning with
endothelial dysfunction to the end with thrombosis and
resultant ischemia.
Fig. 2 Mechanisms explaining homocysteine-related cardiovascular diseases at large. Dark arrow main mechanisms; dotted arrow minor
mechanism. HHcy Hyperhomocysteinemia; NO nitric oxide; DNA deoxyribonucleic acid; ADMA asymmetric dymethyl arginine; ox-LDL oxidized
low density lipoprotein cholesterol; CVD cardiovascular diseases. Through S-nitrosohomocysteine, ADMA and oxidative stress, HHcy reduces NO
bioavailability, thus causing endothelial dysfunction. Under high propensity for coagulation (characterized by platelet adhesion and activation,
production of clotting molecules, impaired fibrinolysis) that can be exacerbated by HHcy, endothelial dysfunction evolves towards atherothrombosis.
Besides, HHcy-related oxidative stress increases ox-LDL production hence leading to formation of the atheromatous plaque which together with arterial
smooth muscle cells proliferation trigger atherosclerosis. Atherosclerosis and atherothrombosis (completed atherosclerosis with ruptured plaque and
thrombosis) lead to CVD
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Beyond these major mechanisms, epigenetics, in
particular DNA hypomethylation resulting from S-
Adenosylhomocysteine accumulation over SAM may
still facilitate atherogenesis by promotion of vascular
smooth-muscle-cell proliferation through an oxidative
stress dependent pathway. This can be seen in cases of
mild to moderate HHcy [36]. Additional triggers of ath-
erosclerosis in HHcy patients include traditional cardio-
vascular risk factors, especially arterial hypertension and
a pro-atherogenic lipid profile with raised ox-LDL that
leads to endothelial dysfunction and macrophage activa-
tion to foam cells within the arterial wall [7].
In rheumatoid arthritis patients
RA is associated with a two-fold increased cardiovascu-
lar risk [1, 2] that persists after adjustment for trad-
itional cardiovascular risk factors, suggesting the pivotal
role of chronic inflammation [2]. More so, inflammatory
biomarkers of cardiovascular risk less prevalent in the
general population are more accurate in the course of
RA [37, 38]. May it be the case for HHcy which is over
two times more frequent in RA patients than in the gen-
eral population (20–42 % versus 5–7 % for RA and gen-
eral populations respectively) [29, 39]. However, only a
few epidemiological studies have investigated the puta-
tive link between HHcy and CVD in RA populations
(Table 1) [10, 21, 40–43]. In a prospective cohort includ-
ing 235 RA patients prospectively followed up during a
time frame of 6.5 year, fatal/non-fatal atherothrombotic
events (myocardial infarction, ischemic heart disease,
stroke, transient ischemic attack, deep vein thrombosis/
pulmonary embolism) were all predicted by high homo-
cysteine levels (OR = 1.96, 95 % CI 0.99–3.50, p = 0.05)
after adjustment for age and sex [10]. In addition, high
Table 1 Studies investigating a link between hyperhomocysteinemia and cardiovascular diseases in rheumatoid arthritis patients
Author, year of
publication, location
Population Study design Cardiovascular
outcome
Key findings Comments
Berglund et al., 2009,
Sweden [10]
235 RA patients; 68
males (52 ± 16 years)a
and 166 females (46 ±
16 years)a
Prospective
cohort study
Atherothrombotic
events
HHcy levels adjusted for age
and sex were a significant
predictor of atherothrombotic
events (OR = 1.96, 95 % CI
0.99–3.50, p = 0.05).
When adjusted for
hypertension alongside
age and sex, The
predictive value of HHcy
was reduced (OR = 1.84,
95 % CI 0.92–3.69, p =
0.084] for hypertension
and OR = 1.80, 95 % CI
0.90–3.59, p = 0.096 for
diabetes mellitus).
Anan et al., 2009,
Japan [40]
25 RA women with WML
(61 ± 6 years)a and and
40 RA women without
WML (60 ± 7 years)a
Case–control
study
WML HHcy independently predicted
WML (OR 1.35, 95 % CI: 1.12-1.63,
p < 0.0001).
Adjusted for the duration
of RA, triglyceride, HDL,
FPG
Dala et al., 2012,
Egypt [41]
180 RA patients with no
history of IHD
Cross-sectional
study
SIHD Serum Hcy was significantly
higher in patients with SIHD as
compared to those without
(p < 0.001)
Chung et al., 2005,
USA [42]
141 patients with RA
(median age 54, IQR
46–64), 68 % of females;
and 86 controls without
RA (median age 52, IQR
44–59), 65.1 % of females
Case–control
study
Coronary-artery
atherosclerosis
(calcification)
In unadjusted comparisons,
HHcy was more common in
RA patients with coronary-artery
calcification than in those without.
After adjusting for age
and sex, the association
was no more significant
Cisternas et al., 2002,
Chili [43]
54 RA patients (51 ±
13 years)a; and 32 age
and sex matched healthy
controls
Case–control
study
History of CVD There were higher Hcy plasma
levels in RA patients with a history
of CVD than in those without.
Seriolo et al., 2001,
Italy [21]
168 female RA women
with WML (cases), 50 ±
10 yearsa; and 72 age
and sex matched healthy
controls (52 ± 9 years)a.
Case–control
study.
History of
thrombotic events
Plasma levels of hcy in aPL
antibody-positive patients with
thrombosis were found to be
significantly higher than in aPL
antibody-negative RA patients
without thrombosis (p < 0.001)
Adjusted for the duration
of RA, triglyceride, HDL-
Cholesterol, fasting
plasma glucose
RA rheumatoid arthritis, SD standard deviation, OR odds ratio, 95% CI 95 % confidence interval, FPG fasting plasma glucose, HHcy hyperhomocysteinemia, White
matter lesions (WML) are considered as ischemic complications of cerebral microvascular disease, and important prognostic factor for the development of stroke,
HDL high density lipoprotein cholesterol, ECG electrocardiogram, Hcy homocysteine, CVD cardiovascular disease, aPL-positive antiphospholipid antibody positive,
aPL-negative antiphospholipid antibody negative, silent ischemic heart disease (SIHD) was diagnosed as ischemia on stress test in the absence of angina and/or
ECG changes of either a bundle branch block or ST segment abnormality consistent with, IHD ischaemic heart disease, IQR interquartile range
aAge is expressed as mean ± standard deviation
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serum total homocysteine concentrations predicted cere-
bral white matter lesions-complications of cerebral micro-
vascular disease- in Japanese RA women after adjustment
for RA duration, serum triglycerides, serum high density
lipoprotein cholesterol, and fasting plasma glucose (OR
1.35, 95 % CI: 1.12-1.63, p < 0.0001) [40].
The pathophysiology of HHcy-derived CVD in RA pa-
tients is largely uncharacterized. Nevertheless, indirect
evidence from relevant observations in the general
population together with the crucial role of inflamma-
tion push forward our understanding of the several
derangements that may interact to cause or exacerbate
it [6, 11, 12, 14, 21, 22, 36–38, 44–51]. They include: i)
oxidative stress [12, 44] ii) chronic inflammation and
immune activation [11, 14, 37, 38, 45] iii) propensity for
a pro-atherogenic lipid profile [44–47] iv) poor disease
status and severe radiological damage [6, 12, 38, 44] v)
thrombophilia [21, 22, 38] vi) increase of plasma ADMA
levels [14, 48] vii) osteoprotegerin [49] viii) genetic and
epigenetic factors [36, 50, 51]. For details, see Table 2.
Unlike in the general population where oxidative
stress, ADMA and a prothrombotic status are the main
determinants of HHcy-dependent CVD, oxidative stress
and long-term shift in immuno-inflammatory activation
are central for the occurrence and worsening of HHcy-
mediated CVD in RA [8]. In fact, excess ROS free radi-
cals released by homocysteine oxidation can enhance the
Nuclear Factor ƙappa B (NF-ƙB) activity already upregu-
lated in RA patients considering NF-ƙB as the master
regulator of expression of inflammation genes [11, 12,
50]. Resultantly, pro-inflammatory biomarkers are exces-
sively released into the circulation, perpetuating
immuno-inflammatory activation [11]. The high inflam-
matory burden collectively with oxidative stress promote
Table 2 Putative mechanisms and factors involved in HHcy-related CVD in RA
Mechanism/factor contributing to HHcy-dependent
CVD
Comment
Oxidative stress [12, 44] Induction of endothelial dysfunction and atherosclerosis throughout impaired NO availability,
increased lipid peroxidation and activation of NF-ƙB by Hcy-derived ROS, thus of inflammatory
cascade
Chronic inflammation and immune activation
[12, 14, 37, 38, 45]
Inflammatory biomarkers (IL-1, IL-6, TNF-α, CRP) are related with impaired NO availability,
endothelial dysfunction, arterial stiffness, and a prothrombotic status
Autoantibodies against peptides modified by homocysteine-thiolactone can worse
inflammation and hence maintain an increased cardiovascular risk [14].
Pro-atherogenic lipid profile [44–47] Healthy HDL molecules are tighly linked to PON1, an antioxidant enzyme which is diminished
in RA
The remaining low HDL is pro-inflammatory and can no longer counteract LDL oxidation
Ox-LDL activates endothelium and favors atherosclerosis
High disease activity and severe radiological
damage [6, 12, 14, 38, 44]
They have been associated with HHcy and both reflect chronic inflammation.
The proatherogenic profile in RA highly depends on disease activity
Antiphospholipid autoantibodies and other
thrombogenic molecules [21, 22, 38]
The prevalence of aPL is high (28 %) in RA
In aPL-positive RA patients, aPL may interact with Hcy to increase the risk of thrombosis
Several procoagulant molecules are correlated with endothelial dysfunction and thrombosis
ADMA [14, 48] Increased plasma ADMA is independently associated with carotid atherosclerosis in RA
ADMA may cause endothelial dysfunction since higher serum levels have been associated with
a decreased CFR in RA
Osteoprotegerina [49] OPG is increased in RA and is independently associated with carotid artery calcification in RA,
probably to counteract increased RANKL production
Considering that HHcy has been associated with OPG in RA, and with respect to Hcy’s ability to
stimulate RANKL, it is possible that OPG is a marker of Hcy-mediated CVD in RA.
Epigenetic and genetic factors [36, 50, 51] Interaction of HHcy with NFKB1-94ATTG ins/del polymorphism constitutively activated in
RA patients to accentuate immune responses and that predispose RA patients to subclinical
and accelerated atherosclerosis
RA is characterized by DNA hypomethylation which is implicated in atherosclerosis in the
general population. It can be hypothesized that it may partly explain CVD in relation to HHcy in
RA patients, but this is yet to be ascertained
CVD cardiovascular diseases, NO nitric oxide, NF- ƙB Nuclear Factor ƙappa B, ROS reactive owxygen species, IL-1 interleukin 1, IL-6 interleukin 6, TNF-α tumor
necrosis factor alpha, CRP C reactive protein, IFN-Ɣ, interferon gamma, HDL high density lipoprotein cholesterol, LDL low density lipoprotein cholesterol, PON1
paroxonase type 1, RA rheumatoid arthritis, ox-LDL oxidized low density lipoprotein cholesterol, IMT increased media-thickness, HHcy hyperhomocysteinemia, aPL
antiphospholipid, ADMA asymmetric dymethylarginine, Hcy homocysteine, CFR coronary flow reserve, Osteoprotegerina soluble glycoprotein which is an inibitor of
the receptor activator of nuclear factor-ƙB (RANKL), OPG osteoprotegerin, CVD cardiovascularv diseases, DNA deoxyribonucleic acid
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excess lipid peroxidation to form ox-LDL [38, 50],
markers of subclinical atherosclerosis in RA [47]. Lipid
peroxidation is sustained and aggravated by a high dis-
ease activity, and activates the endothelium. Besides, ox-
LDL molecules are captured by macrophages, becoming
foam cells that maintain the atherosclerotic plaque pro-
gression through persistent cytokine production [6, 38].
Furthermore, TNF-α promotes vascular smooth-
muscle-cell proliferation. Moreover, IL-1, IL-6 and TNF-
α are procoagulant since they upregulate tissue factor (that
can enter into the injured arterial wall) and trigger endo-
thelial cells to become prothrombotic (alongside oxidative
stress) [37, 38]. Additional prothrombotic markers in the
RA population such as aPL could interact with homocyst-
eine to cause thrombotic events [21, 22]. Hence,
thrombosis-the late phase of atherosclerosis- might
occur as a result of oxidative stress together with pro-
inflammatory biomarkers’ activity and aPL. In brief, the
bi-directional link between homocysteine and immuno-
inflammatory activation [8, 11] well illustrates how
HHcy could contribute to a persistent worsened high
risk for CVD in RA patients.
Folate supplementation, “a therapeutic potential
preventive strategy for cardiovascular outcomes
through homocysteine lowering and blockade”
In the general population
Dozens of studies assessing the benefits of folic acid sup-
plementation on vascular disease have been conducted to
date, initially on animal models. El-Swefi and collaborators
observed a significant increase of plasma NO concentra-
tion in ovariectomized rats co-treated with folic acid and
estradiol compared with ovariectomized and estradiol-
treated groups (15.5 ± 2.8 μmol/l vs 9.4 ± 2.5 μmol/l and
15.5 ± 2.8 μmol/l vs 12.2 ± 3 μmol/l respectively; p < 0.05
for all comparisons). Additionally, folic acid co-treatment
with estradiol resulted in 23 % inhibition of copper-in-
duced lipoprotein oxidation in comparison with the
ovariectomized non-treated group [52]. Likewise,
addition of folic acid to a homocystine-rich diet con-
comitantly reduced the occurrence of damaged cere-
bral vessels and raised glucose transporter protein-1
(a marker of cerebral endothelial dysfunction since it
facilitates glucose transport across blood brain barrier
endothelium) plasma concentration in male Sprague–
Dawley rats after eight weeks [53]. Moreover, vitamin
therapy (B2 or B6 plus B9) intriguingly inhibited
neurologic signs of ischemic cerebral attack (unbal-
ance, ataxia, and convulsions) in spontaneously hyper-
tensive stroke-prone rats [54]. Note that all those
changes were paralleled by homocysteine lowering
[52–54]. Taken together, folic acid supplementation
and subsequent homocysteine lowering might inhibit
oxidative stress (thus reducing lipid peroxidation) and
reverse endothelial dysfunction, with a net benefit on
cerebral vessels.
Along these lines, there is compelling evidence from gen-
eral population studies that folate supplementation reduces
the risk of incident cerebrovascular events (ischemic/
hemorrhagic) [55, 56]. Of particular relevance, a recent
meta-analysis of 26 randomized double-blind placebo-
controlled studies including 58,804 subjects reported a
strong trend in the reduction of future stroke risk of 7 %
(RR 0.93, 0.86 to 1.00; p = 0.05) with folic acid supplemen-
tation [55]. Consistent with this finding, a large double
blinded clinical trial published this year observed a reduced
risk of first stroke attributed to the folic acid-enalapril
combination therapy as compared to enalapril adminis-
tered alone (2.7 % of participants in the enalapril–folic
acid group vs 3.4 % in the enalapril alone group; hazard
ratio 0.79; 95 % CI, 0.68-0.93) [57]. Low baseline folate
levels and high baseline plasma homocysteine were the
main tenants of this benefit [55, 56]. Contrariwise, folic
acid supplements do not prevent incident coronary
heart disease (CHD). This has been suggested by a
meta-analysis of large-scale randomized placebo-
controlled clinical trials held over a five-year period,
and involving 35,603 participants with no heterogeneity
between trials [58].
Furthermore, folic acid supplementation does not ap-
pear beneficial for secondary prevention of CVD [59–61].
In particular, recurrent stroke cannot be prevented with
folate therapy [59]. Additionally, the Vitamins and Throm-
bosis (VITRO) randomized placebo-controlled double
blind trial failed to demonstrate a reduced risk of second-
ary deep veinous thrombosis and pulmonary embolism
after B vitamin therapy [60]. However, it is still inconclu-
sive whether or not folic acid is effective for the prevention
of CHD in persons with previous CVD [59, 61]. The
meta-analysis by Mei and collaborators reported a lack of
efficacy of folic acid supplementation in the prevention of
recurrent CHD (0.94 [0.85–1.04]) [59], same as Qin and
collaborators [61]. Nevertheless, these last authors whose
meta-analysis detected a substantial heterogeneity among
studies observed a trend towards reduced coronary revas-
cularization risk when folic acid and moderate B6 were co-
supplemented. Therefore, the effect of folic acid supple-
mentation on CHD is worthy of definite clarifications.
In total, with the exception of primary prevention of
cerebrovascular events [52–57], current knowledge does
not support the systematic supplementation of folic acid
for CVD primary or secondary prevention in the general
population [58–61]. It has been speculated that HHcy
preferentially targets cerebral microvasculature [55].
This may explain why folic acid therapy works only on
primary prevention of stroke. In addition, it is possible
that cardiovascular changes progress independently of
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homocysteine level once established [62]. This observa-
tion can help understand why folic acid supplementa-
tion does not effect on the prevention of recurrent
CVD. But why is there a disappointment with vitamin
therapy between primary and secondary preventions of
stroke? Folic acid effectiveness might be increased in
the earliest phase of cerebrovascular disease rather than
in the late phase [61]. Following this observation, a
meta-analysis of 14 randomized double-blind placebo-
controlled trials including 732 people reported an
improvement of endothelial dysfunction as measured
by vessel flow mediated dilation after four weeks of
folic acid supplementation, and this effect seemed inde-
pendent of serum homocysteine reduction [30]. These
changes were paralleled by a sharp reduction of total
homocysteine plasma concentration. The findings of
this meta-analysis further support reparation of dam-
aged endothelium by folic acid treatment independently
of plasma homocysteine reduction.
In rheumatoid arthritis
In spite of the acknowledged cardiovascular derangements
of HHcy in RA patients [10, 21, 40–43], we still lack data
regarding the effectiveness of homocysteine-lowering
strategies for CVD prevention in this population. Yet,
almost all prospective studies have clearly demonstrated a
reduction of all-cause CVD morbidity and mortality asso-
ciated with methotrexate treatment [63–65], and this
benefit is thought to be partly confounded by folic acid
supplementation which lowers methotrexate-induced
HHcy [23, 25–28]. Still, the methotrexate-folic acid com-
bination resulted in a reduced mortality hazard ratio of
0.2, compared with 0.5 for methotrexate alone in a RA
cohort probably because of homocysteine lowering via
folic acid supplements [66]. Moreover, a follow-up study
of RA patients showed a rise in plasma homocysteine after
a low-dose methotrexate of 7.5-10 mg/week. Most import-
antly, homocysteine levels were negatively correlated with
folic acid co-treatment [67]. Contrasting with sparse
homocysteine-lowering published studies in RA patients is
their high cardiovascular risk.
It is remarkable that RA patients have a 60 % in-
creased risk of death from myocardial infarction and
stroke compared with the general population [3], and a
48 % increased risk of incident myocardial infarction
[68]. Folic acid depletion and subsequent HHcy-
common in RA patients- partly explain this trend via ex-
cess immuno-inflammatory activation [7, 11, 12, 38, 45].
Furthermore, variations of plasma homocysteine may
significantly predict atherosclerosis progression in RA
patients [69]. Therefore, homocysteine-lowering strat-
egies might be suitable to curtail the CVD ‘epidemic’ in
RA populations.
Learning from general population and animal studies
[55–57] and more than in the general population, folic
acid supplements could reduce incident cerebrovascular
events in the RA population as well if we consider their
high propensity for HHcy and folate deficiency [55–57].
This hypothesis can be further supported by the central
role of oxidative stress in HHcy-mediated cerebrovascular
disease regardless of populations and species [4, 7, 52–54]
together with the likelihood of folic acid to reverse oxida-
tive stress both independently of and via homocysteine
lowering [56, 69]. However, it is questionable whether or
not the likely impact of folate therapy on the cerebral mi-
crovasculature of RA patients extends to coronary and
other peripheral vessels. Extrapolating from general popu-
lation meta-analysis addressing the benefits of vitamin
therapy on extracerebral vessels [59, 61], the answer is a
priori negative. Nonetheless, the positive response cannot
be completely ruled out. Indeed, a meta-analysis of 10 ran-
domized double-blind placebo-controlled clinical trials to-
talizing 2052 subjects reported a significant decrement of
carotid intima-media thickness (CIMT) in relation with
folic acid supplementation, and this benefit was greater
among high CVD risk individuals, with larger homocyst-
eine reduction and higher baseline CIMT values being
strongest predictors [70]. Notably, CIMT is a reliable
marker of atherosclerosis progression and a strong pre-
dictor of future cardiovascular events including CHD in
both general and RA populations [71, 72]. Besides, RA pa-
tients are high CVD risk subjects [1, 3, 6, 68] with higher
baseline CIMT values [72] that steeply rise partly because
of HHcy [69]. Thus, it can be speculated that folic acid
supplementation may also significantly reduce or delay
atherosclerosis progression, consequently preventing all-
cause CVD in RA patients.
Overall, folic acid supplementation is an effective anti-
oxidant therapy which could directly and indirectly limit
immuno-inflammatory activation and lipid peroxidation
as well as repair endothelial damage through oxidative
stress antagonism in RA patients. Furthermore, it may
positively impact on atherosclerosis progression via
plasma homocysteine decrement. In light of these obser-
vations, we put forward the hypothesis that it may offer
therapeutic potentials for CVD prevention in RA patients
in the near future. Large-scale and long-term clinical trials
examining the impact of folic acid supplementation on
CVD in RA populations will be very informative in this
context. In particular, numerous questions should be clari-
fied by the several randomized controlled trials underway
[73]. Is folate supplementation really associated with CVD
risk reduction in RA patients with or without CVD? To
which extent can folate supplementation be beneficial for
CVD prevention in RA patients? What is the precise
mechanism underlying HHcy-related CVD in RA pa-
tients? What are optimal dosage and frequency for folate
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administration? If correct, our hypothesis could have
sizeable public health implications in the issue of CVD in
RA patients. While awaiting, CVD prevention through
systematic supplementation with folic acid is desirable in
both RA patients at high risk for HHcy/folic acid defi-
ciency (e.g., those taking antifolate agents such as metho-
trexate and sulfasalazine, those who have a folate-
deficient diet) and those with ascertained HHcy. A weekly
folic acid dose of five milligrams has been proposed for
those taking methotrexate [10], while other subjects might
be given the current recommended nutrient intake for fo-
lates (1.4 mg week−1) [9] in absence of a specific evidence-
based recommended dose.
Conclusion
CVD may be prevented in RA patients via folic acid
supplementation that potentially lowers plasma homo-
cysteine levels and inhibits/repairs its cardiovascular
health hazards. However, large-scale and long-term
homocysteine-lowering clinical trials with folate are
warranted to conclude on causality of the association
between HHcy and CVD in RA and to definitely clarify
conditions of folate supplementation for a cardiovascu-
lar issue. Anyway, systematic supplement with folic acid
of all RA patients at high risk for folic acid deficiency/
HHcy or those with confirmed HHcy is desirable in
order to prevent CVD.
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